Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Regular Articles
Evidence of Different Pharmacokinetics Including Relationship among AUC, Peak, and Trough Levels between Cyclosporine and Tacrolimus in Renal Transplant Recipients Using New Pharmacokinetic Parameter—Why Cyclosporine Is Monitored by C2 Level and Tacrolimus by Trough Level—
Hironori Takeuchi, Naoto Matsuno, Kayoko Senuma, Toshihiko Hirano, Takayoshi Yokoyama, Shinichiro Taira, Yu Kihara, Kentaro Kuzuoka, Osamu Konno, Yoshimaro Jojima, Abudushukur Mejit, Isao Akashi, Yuki Nakamura, Hitoshi Iwamoto, Koichiro Hama, Tohru Iwahori, Tatsuto Ashizawa, Takeshi Nagao, Tatsunori Toraishi, Kiyoshi Okuyama, Kitaro Oka, Sakae Unezaki
Author information
Keywords: area under the trough level, cyclosporine, tacrolimus, trough concentration, blood concentration at 2 h after administration, area under the concentration time curve
JOURNAL FREE ACCESS

2008 Volume 31 Issue 1 Pages 90-94

Details
Download PDF (524K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

The clinical efficacy of calcineurin inhibitors administered to renal transplant patients is considered to be a strong function of the area under the concentration time curve (AUC). Interestingly, monitoring timings of blood concentrations for two similar calcineurin inhibitors, cyclosporine (CYA; Neoral®) and tacrolimus (TAC; Prograf®) are different. Namely, CYA blood concentration is usually monitored at 2 h after administration (C2) substituted for peak concentration (Cp) and TAC at trough concentration (Ct). In the literature, data describing such characteristics of CYA and TAC have been presented in the past. However, each of these patient groups had different backgrounds. We have attempted to examine the behavior of blood concentration curves simultaneously for both CYA and TAC by establishing controlled groups of renal transplant patients with similar clinical backgrounds. Furthermore, we have analyzed the correlation with Cp and Ct versus AUC implementing area under the trough level (AUTL), or area above the trough level (AATL) as new pharmacokinetic parameters, such that C2 for CYA and Ct for TAC have been verified using controlled clinical data. We have also found distinct differences in the pharmacokinetics between CYA and TAC with the relationships between AUC, Cp, and Ct.

Content from these authors
© 2008 The Pharmaceutical Society of Japan
Previous article Next article
Favorites & Alerts

Recently viewed articles
Share this page
feedback
 Top